Background: Immunosuppressive molecules such as cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), programmed cell death protein (PD-1) and its ligand (PD-L1) are markedly overexpressed in the tumour microenvironment, providing a means for immune escape. Targeting these molecules, novel immunotherapies manipulate the host immune system to better detect and kill cancer cells. This paper describes a case of drug-induced autoimmune colitis and type 1 diabetes mellitus (T1DM) attributed to pembrolizumab. Clinical details: A 70-year-old male presented with a 1-week history of diarrhoea, vomiting, mucositis and loss of appetite following his third treatment with pembrolizumab infusion for metastatic melanoma. The patient's pathology results and clinical symptoms were consistent with a diagnosis of colitis and diabetic ketoacidosis (DKA). Outcomes: The patient's symptoms resolved with interventions from the intensive care unit (ICU), endocrinology and gastroenterology teams. Due to the severity of the adverse drug reaction, pembrolizumab was ceased. The patient was discharged from the hospital with insulin for his T1DM and a 1-month course of weaning prednisolone for his colitis. Conclusion: The potential for autoimmune side effects associated with pembrolizumab may not be fully recognised by all clinicians. This case report highlights the potential for serious adverse events and serves to demonstrate the requirement for clinicians to develop a routine approach for early identification and management of these events.
INTRODUCTION
Australia and New Zealand have the highest rates of melanoma in the world. In Australia alone, melanoma rates have doubled from 1986 to 2006. 1 An estimated 1905 Australians will die from melanoma in 2018. 2 Recent developments have expanded treatment options beyond surgery, chemotherapy and radiotherapy; instead, in selected patients, newer targeted therapies and immunotherapy are increasingly used. Immunotherapy equips the immune system with the means to detect and kill cancer. In order to do this, the immune checkpoint inhibitors target cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1). Overexpression of PD-1 ligands on cancer cells helps provide a means of evasion from host system defences. PD-1 ligands on tumours bind to PD-1 receptors expressed on T cells and result in subsequent T cell deactivation. 3 Pembrolizumab is a recombinant humanised anti-PD-1 receptor monoclonal antibody; it prevents PD-1 signalling resulting in cytotoxic T lymphocyte activation, increases CD4 and CD8 cell counts and restores antitumour immunity. 3 In October 2016, pembrolizumab received approval from the Therapeutic Goods Administration (TGA) for use in unresectable or metastatic melanoma, and has markedly improved the prognosis of these patients. Pembrolizumab requires careful monitoring because it is known to cause immune-related adverse events (irAEs), including (but not limited to) skin reactions, type 1 diabetes mellitus (T1DM), thyroid disorders, hepatitis, colitis, pneumonitis and nephritis. 3, 4 Although these reactions have been described in clinical trials, pembrolizumab is a novel therapy and the true incidence of these serious adverse events is unknown and should be noted during post-marketing surveillance. This case study reviews a patient who developed T1DM and autoimmune colitis as a result of pembrolizumab therapy.
CASE REPORT
A 70-year-old Caucasian man (weight 52 kg, height 170 cm) with no history of diabetes was admitted to the emergency department. He presented with a 1-week history of loss of appetite, worsening diarrhoea (five to six motions per day), polyuria, polydipsia and a single episode of emesis following his third treatment with pembrolizumab infusion (2 mg/kg every 3 weeks) for metastatic melanoma. The patient was diagnosed with and treated for a lumbar melanoma in 2008, but was found to have relapsed progressive disease in 2015 with inguinal and pulmonary involvement. Subsequently, the patient underwent resection and radiotherapy of the inguinal area as well as being started on pembrolizumab. The patient had a history of osteoporosis, juvenile-onset rheumatoid arthritis, common variable immunodeficiency (CVID) and, as a result of a previous blood transfusion, the patient was hepatitis C positive. Evidence of early cirrhosis was apparent on an ultrasound in 2015; consequently the patient was intermittently thrombocytopenic. His regular medications were sulfasalazine 1 g twice daily, naproxen sustained release 750 mg daily when required, colecalciferol 1000 units daily and 21 g intravenous immunoglobulin each month. The patient stopped prophylactic doxycycline 6 months prior to admission, which had been prescribed for pneumonia prophylaxis, having experienced frequent infections secondary to the immunodeficiency. The patient visited his oncologist prior to his presentation at hospital and was started on dexamethasone 8 mg daily for presumed colitis; he commenced the corticosteroid only 1 day prior to admission.
Pathology results on admission showed a blood glucose level of 51 mmol/L, pH 6.99, ketone 6.7 mmol/L and lactate 3.8 mmol/L. Further investigations revealed that the patient also had elevated plasma anti-glutamic acid decarboxylase (GAD) antibodies (>2000 units/mL) suggestive of an autoimmune aetiology of diabetes associated with pembrolizumab.
The patient was admitted to the intensive care unit where several complex issues were addressed, including fulminant diabetic ketoacidosis, autoimmune colitis, mucositis, malnutrition and dehydration. Initial management involved aggressive fluid therapy to restore circulatory volume, correct electrolyte abnormalities and clear ketones. Oral mucositis was symptomatically treated with regular sodium bicarbonate mouthwash and analgesia. Malnutrition was addressed with a low-glucose parenteral nutrition formulation, thiamine and a multivitamin. A neutral human insulin (Novo Nordisk, Actrapid â ) infusion was commenced to lower blood glucose levels (with concomitant potassium replacement via parenteral nutrition). Stool microscopy and culture were performed to rule out infective diarrhoea and a computed tomography (CT) scan was performed to confirm features of colitis. The colitis was initially managed with methylprednisolone 150 mg IV daily with good response; thus, colonoscopy was not required (see Table 1 for the severity scale and recommended treatment algorithm). Parenteral nutrition was ceased after 3 days and the patient was commenced on oral caloric supplements. Concurrently, the Actrapid insulin infusion was ceased and changed to subcutaneous insulin glargine (Sanofi, Lantus â ) 30 units daily and insulin aspart (Novo Nordisk, Novorapid â ) 8 units thrice daily. Initial doses were conservative given parenteral nutrition had ceased and the patient's oral intake may have been erratic. Repeat CT imaging for melanoma restaging demonstrated stable disease with small volume lung metastases previously identified in December 2015.
DISCUSSION
In the treatment of metastatic melanoma, immunotherapies are associated with a substantial survival advantage over cytotoxic chemotherapy. In a Phase I study, Garon et al. 5 demonstrated that there were no dose-limiting toxicities with the administered doses of pembrolizumab. Dosages of 2 mg/kg every 3 weeks and 10 mg/kg every 2 or 3 weeks were associated with objective response rates of up to 62%. 3, 5 Subsequent studies found no clinically relevant differences between the 10 and 2 mg/kg doses. Phase II trials then demonstrated that pembrolizumab 2 mg/kg every 3 weeks improved progression-free survival relative to chemotherapy by 43%. 3, 6 Manipulation of the immune checkpoint molecules (e.g. PD-1 and CTLA-4) may upset intricate immune regulatory processes and lead to autoimmune or inflammatory side effects. The irAEs are not a new phenomenon and have been established following the use of ipilimumab (a CTLA-4 inhibitor). 7 Despite binding to a separate site on T cells, ipilimumab and pembrolizumab share the same overall mechanism of action by preventing T cell deactivation and are thus collectively referred to as 'checkpoint inhibitors'. Compared with CTLA-4, the activity of PD-1 is primarily within the tumour microenvironment; therefore, PD-1 inhibition is less commonly associated with irAEs. The Naranjo scale (https://livertox.nih.gov/Narajo. html, accessed 10 November 2017) was used to establish the probable causal relationship between pembrolizumab and the patient's diagnoses. A score of +6 on the scale suggests that there is a probable link between pembrolizumab and the autoimmune diabetes and colitis. 8 It should be noted that patients with preexisting autoimmune disease (including rheumatoid 9 Although there are little data available to indicate the incidence of irAEs in this patient population, PD-1 inhibitors may be initiated at clinician discretion once potential risks and benefits have been carefully analysed and discussed with the patient.
3,4
The US Food and Drug Administration (FDA) has published risk evaluation and management strategies for the use of ipilimumab. 7 General recommendations for severe or life-threatening immune-mediated toxicities is that the checkpoint inhibitor should be permanently ceased, as occurred in the present case. Previous Phase I, 5 Phase II 6 and Phase III 10 trials investigated the efficacy and safety of pembrolizumab for the treatment of unresectable or metastatic melanoma and non-small cell lung carcinoma. Pooled data from the Phase I and Phase II trials demonstrated that, of the irAEs reported, the most common were hypothyroidism (7.4%), pneumonitis (2.6%) and hyperthyroidism (2.4%). 3 It is worth noting that patients with hepatitis B, hepatitis C, pre-existing autoimmune disease or those who had previously developed severe irAEs to ipilimumab were excluded from these trials.
Among a total of 2117 patients in the Phase I, II and III studies, diarrhoea occurred relatively commonly (13%) compared with immune-mediated colitis (1.7%). 5, 6, 10 Severe (Grade 3-4) immune-mediated colitis was seen in 1.1% of patients, 0.7% having to discontinue therapy. 5, 6, 10 It should be noted that diarrhoea can commonly be caused by non-immune reactions, which may explain the discrepancy in incidence. The patient in the present case reported that diarrhoea began shortly after the initiation of pembrolizumab, and worsened in the days prior to admission. During his admission, Grade 2 colitis was confirmed on imaging with frequent watery stools of up to six times per day (the diagnosis algorithm and treatment guidelines are outlined in Table 1 ). Although it is rare, T1DM and/or diabetic ketoacidosis have been observed with pembrolizumab. 11 Three patients (0.1%) in the Phase I, II and III trials developed immune-mediated T1DM. 5, 6, 10 Six previous case reports have shown that the onset of diabetes is variable, ranging from 3 weeks to 11 months 10-15 (see Table 2 ). Two of the six cases presented with diabetic ketoacidosis and all were managed successfully with insulin therapy (Table 2) . Despite its relatively low occurrence, it is recommended that all patients be routinely monitored for hyperglycaemia or other signs or symptoms of diabetes while being treated with pembrolizumab. 4 The advent of predictive biomarkers may help guide the decision to appropriately prescribe these immunotherapies. 3, 16 There is growing interest in measuring PD-L1 expression to predict the efficacy of these agents; the Phase II study of pembrolizumab demonstrated a 1.7-fold improvement in overall response rates in those who had PD-L1-positive tumours. 6 However, at this point, there is no standardisation or validation for these assays and no global consensus on how a PD-L1-positive tumour should be defined. 16 The growing use of immunotherapies requires clinicians to become increasingly aware of their unique response patterns and side effect profile in order to optimise efficacy and safety. Given their use in an increasing number of malignancies, this case report highlights the need for a consensus approach in the early detection and management of irAEs.
CONCLUSION
Novel immunotherapies such as the PD-1/PD-L1 inhibitors have changed the landscape of metastatic melanoma treatment. Pembrolizumab has demonstrated high activity against melanoma and may be considered easier to manage than previously used chemotherapeutic agents, but the range and severity of its adverse effects may not be fully realised. This case report highlights the potential for serious adverse effects related to pembrolizumab.
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